Cole B Haskins1,2, Bradley D McDowell3, Ryan M Carnahan4, Jess G Fiedorowicz4,5, Robert B Wallace4, Brian J Smith3,6, Elizabeth A Chrischilles4. 1. Department of Epidemiology, College of Public Health, University of Iowa, CPHB, 145 N Riverside Dr, Iowa City, IA, 52242, USA. cole-haskins@uiowa.edu. 2. Medical Scientist Training Program, University of Iowa, Iowa City, IA, USA. cole-haskins@uiowa.edu. 3. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. 4. Department of Epidemiology, College of Public Health, University of Iowa, CPHB, 145 N Riverside Dr, Iowa City, IA, 52242, USA. 5. University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 6. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.
Abstract
PURPOSE: Patients with estrogen receptor positive (ER+) breast cancer are often non-adherent to endocrine therapies, despite clear survival benefits. We utilized a nationally representative cancer cohort to examine the role of specific mental illnesses on endocrine therapy adherence. METHODS: Using the SEER-Medicare database, we included 21,894 women aged 68+ at their first surgically treated stage I-IV ER+ breast cancer during 2007-2013. All had continuous fee-for-service Medicare Parts A and B for 36+ months before, 18+ months after diagnosis, and continuous Part D for 4+ months before, 18+ after diagnosis. Mental illness was defined as occurring in the 36 months prior to cancer onset. We analyzed endocrine therapy adherence, initiation, and discontinuation using longitudinal linear and Cox regression models. RESULTS: Unipolar depression (11.0%), anxiety (9.5%), non-schizophrenia psychosis (4.6%), and dementias (4.6%) were the most prevalent diagnoses. Endocrine therapies were initiated by 80.0% of women. Among those with at least one year of use, 28.0% were non-adherent (< 0.80 adherence, mean = 0.84) and 25.7% discontinued. Patients with dementia or bipolar depression/psychotic/schizophrenia disorders had lower adjusted initiation probabilities by year one of follow-up, versus those without these diagnoses [0.74 95% CI (0.73-0.74) and 0.73 (0.72-0.73), respectively, reference 0.76 (0.76-0.77)]. Patients with substance use or anxiety disorders less frequently continued endocrine therapy for at least one year, after adjustment, [0.85 95% CI (0.85-0.86) and 0.88 (0.87-0.88), respectively, reference 0.90 (0.89-0.90)]. Patients with substance use disorders had 2.3% lower adherence rates (p < 0.001). CONCLUSIONS: Nearly one-quarter of female Medicare beneficiaries have diagnosed mental illness preceding invasive breast cancer. Those with certain mental illnesses have modestly reduced rates of initiation, adherence, and discontinuation and this may help define patients at higher risk of treatment abandonment. Overall, endocrine therapy adherence remains suboptimal, unnecessarily worsening recurrence and mortality risk.
PURPOSE: Patients with estrogen receptor positive (ER+) breast cancer are often non-adherent to endocrine therapies, despite clear survival benefits. We utilized a nationally representative cancer cohort to examine the role of specific mental illnesses on endocrine therapy adherence. METHODS: Using the SEER-Medicare database, we included 21,894 women aged 68+ at their first surgically treated stage I-IV ER+ breast cancer during 2007-2013. All had continuous fee-for-service Medicare Parts A and B for 36+ months before, 18+ months after diagnosis, and continuous Part D for 4+ months before, 18+ after diagnosis. Mental illness was defined as occurring in the 36 months prior to cancer onset. We analyzed endocrine therapy adherence, initiation, and discontinuation using longitudinal linear and Cox regression models. RESULTS: Unipolar depression (11.0%), anxiety (9.5%), non-schizophrenia psychosis (4.6%), and dementias (4.6%) were the most prevalent diagnoses. Endocrine therapies were initiated by 80.0% of women. Among those with at least one year of use, 28.0% were non-adherent (< 0.80 adherence, mean = 0.84) and 25.7% discontinued. Patients with dementia or bipolar depression/psychotic/schizophrenia disorders had lower adjusted initiation probabilities by year one of follow-up, versus those without these diagnoses [0.74 95% CI (0.73-0.74) and 0.73 (0.72-0.73), respectively, reference 0.76 (0.76-0.77)]. Patients with substance use or anxiety disorders less frequently continued endocrine therapy for at least one year, after adjustment, [0.85 95% CI (0.85-0.86) and 0.88 (0.87-0.88), respectively, reference 0.90 (0.89-0.90)]. Patients with substance use disorders had 2.3% lower adherence rates (p < 0.001). CONCLUSIONS: Nearly one-quarter of female Medicare beneficiaries have diagnosed mental illness preceding invasive breast cancer. Those with certain mental illnesses have modestly reduced rates of initiation, adherence, and discontinuation and this may help define patients at higher risk of treatment abandonment. Overall, endocrine therapy adherence remains suboptimal, unnecessarily worsening recurrence and mortality risk.
Authors: S Leonard; L E Adler; K Benhammou; R Berger; C R Breese; C Drebing; J Gault; M J Lee; J Logel; A Olincy; R G Ross; K Stevens; B Sullivan; R Vianzon; D E Virnich; M Waldo; K Walton; R Freedman Journal: Pharmacol Biochem Behav Date: 2001-12 Impact factor: 3.533
Authors: Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut Journal: J Clin Oncol Date: 2010-06-28 Impact factor: 44.544
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: Beomyoung Cho; Maria Pérez; Donna B Jeffe; Matthew W Kreuter; Julie A Margenthaler; Graham A Colditz; Ying Liu Journal: BMC Cancer Date: 2022-08-01 Impact factor: 4.638
Authors: Betina Yanez; Robert J Gray; Joseph A Sparano; Ruth C Carlos; Gelareh Sadigh; Sofia F Garcia; Ilana F Gareen; Timothy J Whelan; George W Sledge; David Cella; Lynne I Wagner Journal: JAMA Oncol Date: 2021-06-17 Impact factor: 33.006
Authors: Blánaid M Hicks; John Busby; Ken Mills; Francis A O'Neil; Stuart A McIntosh; Shu-Dong Zhang; Fabio Giuseppe Liberante; Chris R Cardwell Journal: BMC Cancer Date: 2020-08-24 Impact factor: 4.430
Authors: Barbara L Smith; Conor R Lanahan; Michelle C Specht; Bridget N Kelly; Carson Brown; David B Strasfeld; Jorge M Ferrer; Upahvan Rai; Rong Tang; Travis Rice-Stitt; Anna Biernacka; Elena F Brachtel; Michele A Gadd Journal: Ann Surg Oncol Date: 2020-01-02 Impact factor: 5.344
Authors: Thomas M Kuczmarski; Tim Jaung; Claire E Mancuso; Lee Mozessohn; Lizabeth Roemer; Gregory A Abel; Oreofe O Odejide Journal: Blood Adv Date: 2022-02-22